CSI Market
Sign In | Register

Spyre Therapeutics Inc (SYRE) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access SYRE quarterly Cash Flow →
Quarterly cash flow trends provide additional context on Spyre Therapeutics Inc's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-155.20
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal-10.00
Share-based Compensation37.61
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Investment Income Amortization Of Premium-
Derivative Gain Loss On Derivative Net-
Payment For Discount Premium On Investments Net-
Increase Decrease In Contract With Customer Liability-
Acquired In Process Research And Development-
Change In Fair Value Of Forward Contract Liability-
Operating Lease Right Of Use Asset Asset And Leasehold Improvement Impairment Loss-
Operating Lease Right Of Use Asset Amortization Expense-
Increase Decrease In Operating Lease Liability-
Interest Proceeds Debt Securities2.13
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Accounts Payable7.65
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-0.76
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-12.82
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-37.86
Discontinued operations0.00
Net Cash flow from Operating Activities-169.25
Investing Activities
Capital Expenditures0.00
Sale of Capital Items7.00
Proceeds from Sale and Maturity of Available-for-sale Securities371.74
Payments to Acquire Available-for-sale Securities, Debt-522.21
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-143.48
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock3.31
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net216.35
Proceeds From Issuance Of Common Stock Net Of Payments Of Offering Costs-
Proceeds From Issuance Of Common Stock In Public And At The Market Offerings Net Of Offering Costs-
Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Offering Costs-
Finance Lease Principal Payments-
Exchange Of Stock Amount Exchanged-
Conversion Of Stock Amount Converted-
Asset Acquisition Consideration Transferred Transaction Cost Incurred But Not Yet Paid-
Payment For Deferred Offering Costs-0.16
Deferred Offering Costs Allocated Amount Of Proceeds Of Issuance Of Common Stock0.11
Stock Issued-
Leased Assets Obtained In Exchange For Lease Obligations-
Payment For Settlement Of Share Based Payment Arrangement-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents89.42
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities309.03
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-162.25
Total Cash Flow-3.70
4 historic quarters locked

Sign in to unlock the full Spyre Therapeutics Inc cash flow history.

Sign In Create Free Account

About Spyre Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 19, 2026
  • Source: syre-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001636282-26-000020

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License